Andrew M. Evens, Senior Vice President of RWJBarnabas Health, shared on X:
“Another fun Lymphoma Research Foundation‘s scientific advisory board (SAB) meeting.
A real honor to chair my last in-person meeting with fantastic Lymphoma colleagues.
We reviewed many strong grants and multiple initiatives and projects.
About Lymphoma Consortia and Scientific Workshops
Adolescent and Young Adult (AYA) Lymphoma Consortium:
Lymphomas represent approximately 20% of the nearly 70,000 annual cancer diagnoses among adolescents and young adults (AYAs), introducing distinct clinical and psychosocial complexities.
In response, the Foundation launched its AYA program in 2014 and subsequently established a pioneering AYA Lymphoma Consortium.
The initiative aims to close critical research gaps, enhance clinical outcomes, and provide comprehensive support to young patients throughout their cancer journey via ongoing research collaborations, educational campaigns, and targeted advocacy.
Consensus Recommendations on Treatment Selection and Sequencing in CLL/SLL:
Despite remarkable therapeutic progress in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) over the last decade, a disparity often persists between standard clinical guidelines and routine practice.
To bridge this gap, the Foundation assembled an expert panel to generate consensus strategies for optimal drug selection and treatment sequencing.
Published in Blood Advances in November 2024, these actionable recommendations serve as a key reference for clinicians seeking to refine patient care.
Management of Toxicities After Bispecific Antibody Therapy in Non-Hodgkin Lymphoma:
While bispecific antibodies (bsAbs) represent a promising immunotherapeutic avenue for B-cell lymphomas, their use can lead to substantial adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
To establish safety standards, the Foundation organized a specialized scientific series focused on toxicity management. The consensus guidelines, subsequently published in Blood, aim to mitigate treatment-related risks and enable safer integration of bsAbs into clinical practice.
Read more: Lymphoma Consortia, Initiatives, and Scientific Workshops.”
You can also read: Frontline Mosunetuzumab in Follicular and Marginal Zone Lymphoma: A Response-Adapted Approach
